Radiofrequency ablation of pulmonary tumours: current status.
Radiofrequency ablation (RFA) for thoracic tumours has emerged as a minimally invasive therapy option for primary and secondary lung tumours and has gained increasing acceptance for pain palliation. The procedure is well tolerated and the complication rates are low. RFA provides the opportunity for localized tissue destruction of limited tumour volumes with medium and long term follow-up data suggesting that survival figures do parallel those of non-surgical treatment modalities. The purpose of this article is to review the status of RFA in lung tumours, to emphasize its place in symptomatic palliation and to discuss its potential role in conjunction with radiation or systemic therapy.
Steinke
Karin
K
RBWH, Department of Medical Imaging, Butterfield Street, Herston, Queensland 4029, Australia. karin.steinke@gmail.com
D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging / Q000401:mortality / Q000601:surgery; D017115:Catheter Ablation / Q000009:adverse effects / Q000379:methods; D015179:Colorectal Neoplasms / Q000473:pathology; D003131:Combined Modality Therapy; D019298:Glucose-6-Phosphate / Q000031:analogs & derivatives; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D010166:Palliative Care; D018579:Patient Selection; D010996:Pleural Effusion / Q000209:etiology; D010997:Pleural Neoplasms / Q000000981:diagnostic imaging; D011030:Pneumothorax / Q000209:etiology; D011379:Prognosis; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
C047515:2-fluoro-2-deoxyglucose-6-phosphate; D019298:Glucose-6-Phosphate